A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 11.25 EUR -1.32% Market Closed
Market Cap: 95.6m EUR
APPH
/
Balance Sheet
/
Accumulated Depreciation

Apontis Pharma AG
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Apontis Pharma AG
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
A
Apontis Pharma AG
XETRA:APPH
Accumulated Depreciation
-€659.2k
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck KGaA
XETRA:MRK
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Accumulated Depreciation
-€381k
CAGR 3-Years
-92%
CAGR 5-Years
-38%
CAGR 10-Years
N/A

Apontis Pharma AG
Glance View

Market Cap
93.7m EUR
Industry
Pharmaceuticals

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.

APPH Intrinsic Value
16.07 EUR
Undervaluation 30%
Intrinsic Value
Price
A
What is Intrinsic Value?

See Also

What is Apontis Pharma AG's Accumulated Depreciation?
Accumulated Depreciation
-659.2k EUR

Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Accumulated Depreciation amounts to -659.2k EUR.

What is Apontis Pharma AG's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 3Y
-6%

Over the last year, the Accumulated Depreciation growth was -3%. The average annual Accumulated Depreciation growth rates for Apontis Pharma AG have been -6% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.